West Pharmaceutical Services (WST) Stock Forecast & Price Target

Compare

855 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

WST Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

West

Pharmaceutical Services

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

WST Stock 12 Month Forecast

Average Price Target

$346.38

▲(16.44% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is $346.38 with a high forecast of $390.00 and a low forecast of $275.00. The average price target represents a 16.44% change from the last price of $297.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"208":"$208","391":"$391","253.75":"$253.8","299.5":"$299.5","345.25":"$345.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":390,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$390.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":346.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$346.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$275.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[208,253.75,299.5,345.25,391],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,271.42,280.5415384615385,289.6630769230769,298.7846153846154,307.90615384615387,317.0276923076923,326.14923076923077,335.27076923076925,344.39230769230767,353.51384615384615,362.6353846153846,371.75692307692304,380.8784615384615,{"y":390,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,271.42,277.18615384615384,282.9523076923077,288.71846153846155,294.4846153846154,300.25076923076927,306.0169230769231,311.7830769230769,317.5492307692308,323.31538461538463,329.08153846153846,334.84769230769234,340.61384615384617,{"y":346.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,271.42,271.6953846153846,271.97076923076924,272.24615384615385,272.52153846153846,272.79692307692306,273.0723076923077,273.34769230769234,273.62307692307695,273.89846153846156,274.17384615384617,274.4492307692308,274.7246153846154,{"y":275,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":298.87,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":326.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":340.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.42,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$390.00

Average Price Target$346.38

Lowest Price Target$275.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dan Leonard

UBS

$320→$355

Buy

19.34%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $355 from $320 at UBSWest Pharmaceutical price target raised to $355 from $320 at UBS

Michael Ryskin

Bank of America Securities

$310→$370

Buy

24.38%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $370 from $310 at BofAWest Pharmaceutical price target raised to $370 from $310 at BofA

Patrick B Donnelly

Citi

$350→$375

Buy

26.06%

Upside

Reiterated

10/24/25

West Pharmaceutical Services (WST) Receives a Buy from CitiPatrick Donnelly West Pharmaceutical Services Inc (WST.N) US$307.25 ncBuy 375.00 350.00 ▲ Report

Paul Knight

KeyBanc

$325→$350

Buy

17.66%

Upside

Reiterated

10/24/25

KeyBanc Keeps Their Buy Rating on West Pharmaceutical Services (WST)We release a revised model reflecting 3Q results and FY25 guidance, raising our PT from $325 to $350.

Justin Bowers

Deutsche Bank

$305→$345

Buy

15.98%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $345 from $305 at Deutsche BankWest Pharmaceutical price target raised to $345 from $305 at Deutsche Bank

Jack Scalprey

TR | OpenAI - 4o

$313→$346

Buy

16.31%

Upside

Reiterated

10/24/25

AI Generated ArticleAI Generated Article

Luke Sergott

Barclays

$275

Hold

-7.55%

Downside

Reiterated

10/24/25

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Community Health (NYSE: CYH) and West Pharmaceutical Services (NYSE: WST)

Daniel Markowitz CFA

Evercore ISI

$350→$390

Buy

31.11%

Upside

Reiterated

10/23/25

West Pharmaceutical price target raised to $390 from $350 at Evercore ISIWest Pharmaceutical price target raised to $390 from $350 at Evercore ISI

Matt Larew

William Blair

―

Buy

―

Reiterated

10/23/25

Strong Q3 Performance and Raised 2025 Guidance Justify Buy Rating for West Pharmaceutical ServicesWest Pharmaceutical Services, Inc. (WST) - Across-the-Board Beat and Raise Driven by HVP Components From: , Thursday, October 23, 2025 11:28 AM Research | Services, Inc.

Jamie Clark

Rothschild & Co Redburn

$311

Buy

4.55%

Upside

Initiated

09/15/25

West Pharmaceutical Services (WST) Has a New Rating from Redburn AtlanticRothschild Redburn analyst Jamie Clark initiates coverage on West Pharmaceutical (NYSE: WST) with a Buy rating and a price target of $311.00.

David Windley

Jefferies

$245→$335

Buy

12.62%

Upside

Reiterated

07/25/25

Jefferies Sticks to Their Buy Rating for West Pharmaceutical Services (WST)West Pharmaceutical (WST, BUY, PT $335) – Raise PT to $335, maintain Buy.

Nico Chen

DBS

$265

Buy

-10.92%

Downside

Reiterated

06/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (NYSE: WST), Blueprint Medicines (NASDAQ: BPMC) and Vera Therapeutics (NASDAQ: VERA)

Doug Schenkel

Wolfe Research

―

Hold

―

Initiated

12/13/24

West Pharmaceutical initiated with a Peer Perform at Wolfe ResearchWest Pharmaceutical initiated with a Peer Perform at Wolfe Research

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dan Leonard

UBS

$320→$355

Buy

19.34%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $355 from $320 at UBSWest Pharmaceutical price target raised to $355 from $320 at UBS

Michael Ryskin

Bank of America Securities

$310→$370

Buy

24.38%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $370 from $310 at BofAWest Pharmaceutical price target raised to $370 from $310 at BofA

Patrick B Donnelly

Citi

$350→$375

Buy

26.06%

Upside

Reiterated

10/24/25

West Pharmaceutical Services (WST) Receives a Buy from CitiPatrick Donnelly West Pharmaceutical Services Inc (WST.N) US$307.25 ncBuy 375.00 350.00 ▲ Report

Paul Knight

KeyBanc

$325→$350

Buy

17.66%

Upside

Reiterated

10/24/25

KeyBanc Keeps Their Buy Rating on West Pharmaceutical Services (WST)We release a revised model reflecting 3Q results and FY25 guidance, raising our PT from $325 to $350.

Justin Bowers

Deutsche Bank

$305→$345

Buy

15.98%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $345 from $305 at Deutsche BankWest Pharmaceutical price target raised to $345 from $305 at Deutsche Bank

Jack Scalprey

TR | OpenAI - 4o

$313→$346

Buy

16.31%

Upside

Reiterated

10/24/25

AI Generated ArticleAI Generated Article

Luke Sergott

Barclays

$275

Hold

-7.55%

Downside

Reiterated

10/24/25

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Community Health (NYSE: CYH) and West Pharmaceutical Services (NYSE: WST)

Daniel Markowitz CFA

Evercore ISI

$350→$390

Buy

31.11%

Upside

Reiterated

10/23/25

West Pharmaceutical price target raised to $390 from $350 at Evercore ISIWest Pharmaceutical price target raised to $390 from $350 at Evercore ISI

Matt Larew

William Blair

―

Buy

―

Reiterated

10/23/25

Jamie Clark

Rothschild & Co Redburn

$311

Buy

4.55%

Upside

Initiated

09/15/25

David Windley

Jefferies

$245→$335

Buy

12.62%

Upside

Reiterated

07/25/25

Jefferies Sticks to Their Buy Rating for West Pharmaceutical Services (WST)West Pharmaceutical (WST, BUY, PT $335) – Raise PT to $335, maintain Buy.

Nico Chen

DBS

$265

Buy

-10.92%

Downside

Reiterated

06/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (NYSE: WST), Blueprint Medicines (NASDAQ: BPMC) and Vera Therapeutics (NASDAQ: VERA)

Doug Schenkel

Wolfe Research

―

Hold

―

Initiated

12/13/24

West Pharmaceutical initiated with a Peer Perform at Wolfe ResearchWest Pharmaceutical initiated with a Peer Perform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering West Pharmaceutical Services

1 Month

xxx

Success Rate

7/9 ratings generated profit

Average Return

+3.14%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 77.78% of your transactions generating a profit, with an average return of +3.14% per trade.

3 Months

xxx

Success Rate

9/13 ratings generated profit

Average Return

+6.98%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +6.98% per trade.

1 Year

Paul KnightKeyBanc

Success Rate

10/13 ratings generated profit

Average Return

+14.34%

reiterated a buy rating 3 days ago

Copying Paul Knight's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +14.34% per trade.

2 Years

xxx

Success Rate

9/13 ratings generated profit

Average Return

+20.40%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +20.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WST Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, WST has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. WST average Analyst price target in the past 3 months is 346.38.

Each month's total comprises the sum of three months' worth of ratings.

WST Financial Forecast

WST Earnings Forecast

Next quarter’s earnings estimate for WST is $1.83 with a range of $1.78 to $1.88. The previous quarter’s EPS was $1.96. WST beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year WST has Preformed in-line its overall industry.

WST Sales Forecast

Next quarter’s sales forecast for WST is $796.61M with a range of $790.39M to $804.62M. The previous quarter’s sales results were $804.30M. WST beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year WST has Preformed in-line its overall industry.

WST Stock Forecast FAQ

What is WST’s average 12-month price target, according to analysts?

Based on analyst ratings, West Pharmaceutical Services, Inc.’s 12-month average price target is 346.38.

What is WST’s upside potential, based on the analysts’ average price target?

West Pharmaceutical Services, Inc. has 16.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is WST a Buy, Sell or Hold?

West Pharmaceutical Services, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is West Pharmaceutical Services, Inc.’s price target?

The average price target for West Pharmaceutical Services, Inc. is 346.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $390.00 ,the lowest forecast is $275.00. The average price target represents 16.44% Increase from the current price of $297.47.

What do analysts say about West Pharmaceutical Services, Inc.?

West Pharmaceutical Services, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of WST?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

West Pharmaceutical Services (WST) Stock Forecast & Price Target

WST Analyst Ratings

WST Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering West Pharmaceutical Services

WST Analyst Recommendation Trends

WST Financial Forecast

WST Earnings Forecast

WST Sales Forecast

WST Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts